The effectiveness of Pfizer’s COVID-19 vaccine in preventing symptomatic infection drops by more than 10 percent after six months, the company said on July 28.
The two-dose vaccine, developed in conjunction with Germany’s BioNTech, was found to be 96 percent effective for the first two months following the second dose, according to a study from the companies’ scientists.
